Targets › TPO
1 program from 1 company in 1 trial: 1 Phase 4; Metabolic and endocrine; next expected readout Jul 2030.
Iodination and coupling of the hormonogenic tyrosines in thyroglobulin to yield the thyroid hormones T(3) and T(4). (UniProt, P07202)
Open in Phaseline: the race on TPO, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The First Affiliated Hospital with Nanjing Medical University | Methimazole Thyroid peroxidase inhibitor | TPO | Phase 4 | Graves Disease | Jul 2030 |
Graves Disease (1)
small molecule (1)
The First Affiliated Hospital with Nanjing Medical University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.